Missouri Roundup Lawsuits After the Supreme Court’s Monsanto v. Durnell Ruling: What Cancer Victims Need to Know
You may have seen the television advertisements for years — the ones that said if you used Roundup and developed cancer, you could file a lawsuit and recover. Those ads ran for years because, for years, they were true. Juries across the country looked at the science connecting glyphosate to non-Hodgkin’s lymphoma and returned verdicts against Monsanto. Then the Supreme Court of the United States changed the ground beneath every one of those cases. On June 25, 2026, in a 7-2 decision called Monsanto Co. v. Durnell, No. 24-1068, the Court held that federal pesticide law preempts the primary legal theory those verdicts were built on — and it did so in a case that started right here in Missouri, with a groundskeeper who developed cancer after years of Roundup exposure at work.
If you are reading this page, you probably used Roundup. You may have a cancer diagnosis. You are searching for whether the courthouse door is still open to you. We are going to tell you the truth about that — all of it, including the parts other firms’ websites are not telling you. Most of the pages you will find online were written before the Durnell decision. They still say “file your Roundup lawsuit today” as though nothing has changed. Something has changed, and it is enormous. But it is not the end of the story, and it is not the end of every possible claim. What it is, is the closing of one road — the main road — and the narrowing of the fight to paths that fewer lawyers know how to walk.
We are Attorney911 — The Manginello Law Firm, PLLC. We handle toxic tort cases, product liability cases, and the kind of corporate-accountability litigation that requires a trial team willing to tell a client the hard truth and then fight from wherever that truth leaves them. That is what this page is. The hard truth first. Then the fight.
What Just Happened: The Supreme Court Closed the Main Door
The Supreme Court held that the Federal Insecticide, Fungicide, and Rodanticide Act — known as FIFRA — expressly preempts state-law failure-to-warn claims against Monsanto for Roundup exposure where the claim would require Monsanto to add a cancer warning to its Roundup products’ label. Monsanto Co. v. Durnell, No. 24-1068 (U.S. June 25, 2026). The vote was 7-2. Justice Kavanaugh delivered the opinion of the Court, joined by Chief Justice Roberts and Justices Thomas, Alito, Sotomayor, Kagan, and Barrett. Justice Jackson dissented, joined by Justice Gorsuch. The Court reversed the Missouri Court of Appeals, Eastern District, which had upheld the verdict for the plaintiff.
Here is what that means in plain English. For years, the central legal theory in Roundup cancer lawsuits was failure to warn — the argument that Monsanto knew or should have known that glyphosate was associated with an elevated risk of non-Hodgkin’s lymphoma, and that it failed to put an adequate cancer warning on the Roundup label. That theory produced verdicts. It produced settlements. It was the engine of the entire Roundup mass tort. The Supreme Court just pulled that engine out of the car.
The reasoning works like this. Glyphosate, the active ingredient in Roundup, is a pesticide registered under FIFRA. Under FIFRA, no person in any state may distribute or sell any pesticide that is not registered with the EPA, and the EPA reviews and approves the pesticide’s labeling as part of that registration. 7 U.S.C. § 136a(a). The EPA has consistently maintained that glyphosate is “not likely to be carcinogenic to humans.” FIFRA also contains an express preemption clause — 7 U.S.C. § 136v(b) — which prohibits states from imposing labeling or packaging requirements “in addition to or different from” those required under FIFRA. The Supreme Court held that a state-law failure-to-warn claim that would require Monsanto to add a cancer warning to its Roundup label is exactly the kind of “in addition to or different from” requirement that FIFRA preempts. Because the EPA approved Roundup’s label without a cancer warning, and because the EPA’s position is that glyphosate is not likely carcinogenic, a state court cannot order Monsanto to add one — even if a jury thinks the science says otherwise.
That is the main door, closed. A Missouri jury heard the evidence, weighed the science, and returned a verdict for a man who handled Roundup for years and then developed non-Hodgkin’s lymphoma. The Missouri courts upheld that verdict. The Supreme Court overturned it. And in doing so, the Court did not just reverse one Missouri case — it established a rule that applies in every state, including Idaho, Texas, and every other jurisdiction where a person might have been exposed to Roundup and developed cancer.
But here is what the Court did NOT do, and this is where the page every other firm has not updated becomes the page that fails the reader. The Supreme Court granted certiorari on a limited question: “Whether the Federal Insecticide, Fungicide, and Rodanticide Act preempts a label-based failure-to-warn claim where EPA has not required the warning.” Monsanto Co. v. Durnell, No. 24-1068 (U.S. June 25, 2026). The Court answered that question yes. It did not answer whether FIFRA preempts every tort theory a plaintiff might bring against a pesticide manufacturer. It did not address design defect claims. It did not address negligent testing claims. It did not address manufacturing defect claims. It answered one question — the labeling question — and left the rest for another day.
That distinction — between what the Court decided and what it left open — is the entire fight now. And it is a fight most of the internet does not even know exists.
The Science: Glyphosate, IARC, and Non-Hodgkin’s Lymphoma
To understand what is at stake — and why the Durnell decision is not just a legal abstraction but a human catastrophe for thousands of families — you need to understand what glyphosate does in the human body, what the scientific dispute actually is, and what non-Hodgkin’s lymphoma does to the people who develop it.
Glyphosate is a broad-spectrum systemic herbicide. It works by inhibiting an enzyme pathway — the shikimate pathway — that plants rely on to synthesize essential amino acids. The pathway does not exist in humans, which is part of why the EPA has concluded that glyphosate is “not likely to be carcinogenic to humans.” But the absence of the pathway in human cells does not end the scientific inquiry, because carcinogenesis is not always a direct enzyme-pathway process. The question is whether glyphosate or its formulations cause cellular damage through other mechanisms — oxidative stress, endocrine disruption, immune system alteration, or genotoxic effects on human lymphocytes — and whether epidemiological evidence supports an association between glyphosate exposure and specific cancers.
That is where the scientific community split. In 2015, the International Agency for Research on Cancer — IARC, the cancer research arm of the World Health Organization — classified glyphosate as “probably carcinogenic to humans,” a Group 2A classification. IARC’s assessment was based on a review of epidemiological studies showing associations between glyphosate exposure and non-Hodgkin’s lymphoma, along with mechanistic and animal-study evidence. The EPA’s assessment, conducted under FIFRA’s registration review process, reached the opposite conclusion — that glyphosate is “not likely to be carcinogenic to humans.” This divergence between two authoritative scientific bodies is not a minor academic disagreement. It is the foundation of the entire legal conflict. When a plaintiff argues that Monsanto should have warned about cancer risks, the plaintiff is relying on IARC’s classification and the epidemiological evidence supporting it. When Monsanto argues that FIFRA preempts that claim, it is relying on the EPA’s contrary assessment and the fact that the EPA-approved label does not carry a cancer warning.
Non-Hodgkin’s lymphoma is a cancer of the lymphatic system, specifically affecting lymphocytes — the white blood cells that are part of the body’s immune defense. It is not a single disease but a group of more than 70 subtypes, classified by the type of lymphocyte affected (B-cell or T-cell), the growth pattern (indolent or aggressive), and the specific molecular characteristics of the tumor. The most common subtype in the United States is diffuse large B-cell lymphoma, an aggressive form that requires immediate treatment.
The diagnosis typically begins with a lymph node biopsy — a surgical procedure to remove or sample an enlarged lymph node for pathological examination. The pathologist identifies the lymphoma subtype through immunohistochemistry and flow cytometry, which stain and sort the malignant cells by their surface markers. This subtype identification is critical because treatment varies dramatically by type. Once the subtype is confirmed, staging follows — CT scans, PET scans, and sometimes bone marrow biopsies to determine how widely the disease has spread.
Treatment for non-Hodgkin’s lymphoma is aggressive and costly. The backbone of treatment for most B-cell lymphomas is a chemotherapy regimen called R-CHOP — rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone — typically delivered in six cycles over approximately four months. Rituximab is a monoclonal antibody that targets the CD20 protein on B-cells; it represents the immunotherapy component of the regimen. For localized disease, radiation therapy may be added. For relapsed or refractory cases — cases where the lymphoma returns or does not respond to initial treatment — the treatment escalates to high-dose chemotherapy followed by autologous stem cell transplantation, a grueling process that involves harvesting the patient’s own stem cells, administering near-lethal doses of chemotherapy to destroy the bone marrow, and then reinfusing the stem cells to rebuild the immune system. In recent years, CAR-T cell therapy — a treatment in which the patient’s own T-cells are genetically engineered to attack the lymphoma — has become available for certain relapsed cases, at costs that can exceed $400,000 per treatment course.
The lifetime cost of treating non-Hodgkin’s lymphoma — including initial therapy, surveillance imaging, relapse treatment, and management of long-term side effects — can reach well into seven figures. The economic losses extend beyond medical bills: lost wages during treatment, diminished earning capacity from fatigue and cognitive effects (“chemo brain”), and the ongoing cost of oncologic surveillance that continues for years or decades. The non-economic losses — the pain of infusion after infusion, the fear of relapse that never fully recedes, the quality of life surrendered to a disease you believe a corporation’s product gave you — are the losses a jury is supposed to be allowed to value. The Durnell decision, for failure-to-warn claims, removes that jury from the equation.
This is the medicine behind the legal abstraction. When the Supreme Court held that FIFRA preempts failure-to-warn claims, it did not just overturn a legal theory. It told thousands of people who handle Roundup at work — groundskeepers, landscapers, farmers, agricultural workers, nursery employees, park maintenance crews, and homeowners who sprayed it in their yards for years — that the primary legal path to holding Monsanto accountable for their cancer is closed. Whether every path is closed is a different question, and that is where the fight now lives.
FIFRA Preemption: How a Federal Pesticide Law Became a Corporate Shield
To understand why the Supreme Court’s decision is so devastating — and why it is also more limited than it first appears — you need to understand how FIFRA works, what its preemption clause actually says, and how Monsanto turned a regulatory compliance argument into constitutional immunity.
FIFRA is the federal statute that governs the registration, sale, and distribution of pesticides in the United States. Under FIFRA, no person in any state may distribute or sell any pesticide that is not registered with the EPA. 7 U.S.C. § 136a(a). To obtain a registration, the applicant must submit a complete copy of the pesticide’s labeling, a statement of all claims to be made for it, and any directions for its use. 7 U.S.C. § 136a(c)(1)(C). The EPA registers the pesticide only upon determining that its labeling and other required materials comply with FIFRA’s requirements. 7 U.S.C. § 136a(c)(5)(B). This means the EPA reviews the label — the warnings, the directions, the safety statements — and approves it as part of the registration process. Once approved, that label is the label the manufacturer may use.
FIFRA also contains a preemption clause — 7 U.S.C. § 136v(b) — which provides that states shall not impose or continue in effect any requirements for labeling or packaging in addition to or different from those required under FIFRA. This is express preemption — Congress’s direct command that states cannot add their own labeling requirements on top of what FIFRA requires. The question in Durnell was whether a state-law failure-to-warn claim — a tort claim arguing that Monsanto should have put a cancer warning on the Roundup label — constitutes a “requirement for labeling” that is “in addition to or different from” what FIFRA requires. The Supreme Court held that it does.
The argument that carried the majority was straightforward: if a state court jury orders Monsanto to add a cancer warning to Roundup’s label, that court has imposed a labeling requirement different from the one the EPA approved. The EPA approved Roundup’s label without a cancer warning because the EPA concluded glyphosate is not likely carcinogenic. A state-law claim requiring a cancer warning directly contradicts that federal regulatory judgment. Under the Supremacy Clause, federal law wins. FIFRA’s express preemption clause makes this explicit — states cannot impose labeling requirements different from FIFRA’s.
Justice Kavanaugh’s opinion turned EPA registration into a liability shield. If the EPA approves a pesticide label without a particular warning, and FIFRA prohibits states from requiring additional warnings, then a manufacturer who complies with the EPA-approved label is — at least for failure-to-warn purposes — immune from state tort liability for not adding that warning. The fact that a jury might find the science supports a cancer warning does not matter. The fact that IARC classified glyphosate as probably carcinogenic does not matter. What matters is what the EPA-approved label says, and FIFRA says no state can require anything different.
This is the mechanism. A federal regulatory agency’s assessment — the EPA’s conclusion that glyphosate is “not likely to be carcinogenic” — has been converted, through the preemption clause, into an absolute bar on state-law claims seeking a different warning. The agency’s scientific judgment, even if disputed by another authoritative scientific body, even if contradicted by epidemiological evidence, controls what a state court jury can and cannot do. The jury is not permitted to hear the failure-to-warn claim at all.
But here is what makes the Durnell ruling narrower than the headlines suggest. The Supreme Court granted certiorari on one specific question: whether FIFRA preempts a label-based failure-to-warn claim where the EPA has not required the warning. The Court answered that question. It did not hold that FIFRA preempts every tort claim against a pesticide manufacturer. It did not hold that a manufacturer who complies with FIFRA is immune from all state-law liability. It held that FIFRA preempts claims that would require labeling changes — claims that, if successful, would impose a “requirement for labeling or packaging” different from what FIFRA mandates.
The difference between “FIFRA preempts failure-to-warn claims” and “FIFRA preempts all tort claims” is the difference between a closed door and a sealed building. The door on failure-to-warn claims is closed. Whether the building is sealed is a question the Court has not answered — and the answer, as the next section explains, comes from a case the Court decided more than two decades ago.
What the Court Did NOT Decide: The Theories That May Survive
In 2005, the Supreme Court decided Bates v. Dow Agrosciences LLC, 544 U.S. 431 — a case involving Texas cotton farmers whose crops were damaged by a herbicide called Strongarm. The farmers sued the manufacturer under several state-law theories, including failure to warn, design defect, negligent testing, and manufacturing defect. The manufacturer argued that FIFRA preempted all of those claims. The Supreme Court disagreed — and in doing so, it drew a line that the Durnell Court did not erase.
The Bates Court held that FIFRA’s preemption clause — the same 7 U.S.C. § 136v(b) at issue in Durnell — does not preempt state-law claims that are not predicated on labeling requirements. The Court explained:
“None of these common-law rules requires that manufacturers label or package their products in any particular way. Thus, petitioners’ claims for defective design, defective manufacture, negligent testing, and breach of express warranty are not pre-empted.”
Bates v. Dow Agrosciences LLC, 544 U.S. 431, 444 (2005). This is the holding that survives Durnell. Design defect claims, negligent testing claims, manufacturing defect claims, and breach of express warranty claims are not preempted by FIFRA because they do not impose labeling requirements. They are predicated on independent duties — the duty to design a reasonably safe product, the duty to test a product with reasonable care, the duty to manufacture a product free of defects — none of which require the manufacturer to change its label.
Here is what this means for a person who used Roundup and developed non-Hodgkin’s lymphoma after the Durnell decision. The failure-to-warn claim — the argument that Monsanto should have put a cancer warning on the label — is preempted. A court will likely dismiss that claim at the pleading stage. But a design defect claim — the argument that Roundup was defectively designed because its carcinogenic risks could have been reduced or eliminated through alternative formulations — is not preempted under Bates, because that claim does not require Monsanto to change its label. It requires Monsanto to have designed a different product. A negligent testing claim — the argument that Monsanto failed to exercise reasonable care in researching and testing glyphosate’s carcinogenic potential — is not preempted under Bates, because that claim does not require Monsanto to change its label. It requires Monsanto to have conducted adequate testing. A manufacturing defect claim — the argument that a particular batch of Roundup contained a defect that made it more carcinogenic than the product as designed — is not preempted, because that claim addresses the manufacturing process, not the label.
The Bates Court also addressed fraud claims — and this is where the analysis becomes more nuanced. The Court held that fraud claims are “premised on common-law rules that qualify as ‘requirements for labeling or packaging’” and are therefore subject to preemption under 7 U.S.C. § 136v(b) only to the extent they impose labeling requirements “in addition to or different from” FIFRA’s standards. Bates, 544 U.S. at 446. A fraud claim that argues Monsanto made false statements on its EPA-approved label would be preempted because it would require a labeling change. But a fraud claim predicated on independent statements — statements made to the scientific community, to regulators during the registration process, or to the public outside the label — may survive, because those claims do not require the manufacturer to change its label.
The critical distinction, then, is between claims that require labeling changes and claims that do not. Durnell closed the first category. Bates left the second category open. The question for any post-Durnell Roundup case is whether the plaintiff’s claims can be framed as independent-duty claims — design defect, negligent testing, manufacturing defect — rather than as labeling claims in disguise.
This is not a theoretical distinction. It is the line that determines whether a person with non-Hodgkin’s lymphoma has a case or does not. And it is a line that most of the legal content on the internet does not even mention, because most of that content was written before Durnell and assumes the failure-to-warn theory is still available. It is not. The failure-to-warn theory is dead. The question is whether the surviving theories — the ones Bates preserved — can carry the weight of a case that the failure-to-warn theory used to carry alone.
The honest answer is: maybe. A design defect claim against Roundup faces challenges that a failure-to-warn claim did not. To prove design defect, a plaintiff must show that Roundup was unreasonably dangerous as designed — that its carcinogenic risks outweighed its utility, or that a safer alternative formulation was available and feasible. This requires expert testimony on pesticide chemistry, toxicology, and alternative formulation — testimony that is more complex than the warning-label evidence that powered the failure-to-warn verdicts. A negligent testing claim requires evidence of what Monsanto knew about glyphosate’s carcinogenic potential, what testing it conducted, what testing it should have conducted, and how its testing fell below the standard of care. This requires discovery into Monsanto’s internal research records — documents that may exist in the MDL discovery record from prior Roundup litigation but that will require independent subpoenas and active litigation to obtain.
The Durnell dissent — authored by Justice Jackson and joined by Justice Gorsuch — may also point the way for future challenges. An unusual pairing of a liberal and conservative justice suggests the preemption issue is not ideologically settled in the way the 7-2 majority might suggest at first glance. Dissents can become roadmaps for future cert petitions, for legislative action, and for narrowing subsequent appellate interpretations of the majority’s holding. The dissent’s reasoning — whatever it argued about the limits of FIFRA preemption or the role of state tort law in supplementing federal regulatory schemes — is a signal that the preemption doctrine may not have the final word.
What a generalist gets wrong here — and what the lawyer down the street may not know — is that Durnell is not a blanket immunity ruling. It is a narrow preemption ruling on a specific type of claim. Filing a post-Durnell Roundup case that pleads only failure-to-warn will result in dismissal. Filing a case that pleads design defect, negligent testing, and manufacturing defect — grounded in the independent-duty language of Bates — is a different case that a court must evaluate under a different legal standard. The lawyer who reads Durnell as “Roundup cases are over” will not file the case that Bates preserves. The lawyer who reads Durnell as “failure-to-warn is over, but Bates is still good law” will file a different case — and that is the case worth filing.
Monsanto and Bayer: The Corporate Structure Behind the Shield
Monsanto Company is the manufacturer of Roundup. It is also, since 2018, a division of Bayer AG — the German pharmaceutical and life sciences conglomerate that acquired Monsanto in a transaction valued at approximately $63 billion. Bayer absorbed Monsanto’s name, its product portfolio, and its litigation portfolio — including tens of thousands of Roundup cancer lawsuits that were pending at the time of the acquisition and that have continued to accumulate since.
The Monsanto-Bayer relationship matters for several reasons. First, Bayer is the entity with the financial resources to litigate these cases at the highest level — to retain the Supreme Court litigators who argued Durnell, to fund multi-year lobbying campaigns in state legislatures, and to absorb the settlement costs of pre-Durnell cases while pursuing the preemption defense that closes the door on future cases. Second, the acquisition means that Monsanto’s internal corporate documents — the research records, the internal communications about glyphosate’s carcinogenicity, the interactions with EPA officials during registration reviews — are now Bayer’s documents, and they are discoverable in litigation that survives the Durnell preemption bar.
The corporate strategy that culminated in Durnell was not a single move. It was a multi-year, multi-front campaign. According to public reporting, Bayer deployed lobbyists and campaign contributions in multiple states — including Idaho — to secure product liability immunity legislation that would have shielded the company from state-law tort claims at the legislative level. In Idaho, that effort was reported to have included direct lobbying of state legislators and funding of political action committees during the 2024 and subsequent legislative sessions. The proposed legislation would have created a statutory immunity for herbicide manufacturers whose products were registered with the EPA — essentially codifying at the state level the same preemption defense that Durnell later established at the federal level. The Idaho legislative effort was blocked by sustained opposition, but the federal judicial effort succeeded.
This two-front strategy — state legislative immunity as a backup to federal preemption — is important because it reveals the corporate playbook. When state legislative immunity fails, the manufacturer pivots to federal preemption. When federal preemption succeeds at the Supreme Court, the state legislative effort becomes unnecessary. The result is the same: a liability shield that insulates the manufacturer from the tort claims that juries were using to hold it accountable.
The corporate structure also matters for identifying who is actually on the hook. Monsanto is the named defendant in the Roundup litigation, but Bayer is the parent corporation that controls Monsanto’s operations, finances its litigation defense, and bears the ultimate financial responsibility for any judgments or settlements. In any surviving post-Durnell case, the defendant is Monsanto Company, but the financial backing — and the discovery target for internal corporate documents — extends to Bayer AG and its corporate family.
For a plaintiff, this means the defendant is not a small company that might be unable to satisfy a judgment. Bayer AG is one of the largest pharmaceutical and chemical companies in the world, with annual revenue exceeding $50 billion. If a non-preempted claim succeeds — if a design defect or negligent testing claim survives and produces a verdict — the defendant has the resources to pay it. The barrier is not the defendant’s solvency. The barrier is the legal door that Durnell closed on the primary theory and the uncertainty of whether the surviving theories can produce results.
Idaho’s Legislative Battle: When the Statehouse Almost Closed the Door Too
The article that brought this case to our attention came from Idaho — and the Idaho story is not a side note. It is the other half of the same strategy. While Bayer was building its preemption argument for the Supreme Court, it was also pursuing state-level legislation designed to achieve the same immunity through a different branch of government.
Idaho’s state legislature convenes in Boise. During the 2024 and subsequent legislative sessions, a herbicide liability-immunity bill was reportedly introduced that would have shielded manufacturers of EPA-registered pesticides from state-law tort claims. The argument for the bill was the same argument that succeeded in Durnell: if the EPA has approved the product’s label, the manufacturer should not be subject to state-law claims seeking additional warnings or different safety requirements. The argument against the bill was that federal regulatory approval is not a guarantee of safety — that the EPA’s assessment can be wrong, can be based on incomplete data, and can be influenced by the manufacturer’s own submissions — and that state tort law is an essential backstop when federal regulation fails to protect the public.
The Idaho bill died after sustained opposition. But its existence — and the lobbying effort behind it — reveals the strategy. When the legislative route fails, the judicial route becomes the primary path. Durnell is the judicial route succeeding where the legislative route failed. The combination of the two efforts — state legislative immunity as Plan A, federal preemption as Plan B — shows a coordinated, well-funded campaign to close every door a plaintiff might use to hold the manufacturer accountable.
For Idaho residents who used Roundup and developed non-Hodgkin’s lymphoma, this means the threat to their legal rights came from two directions. The state legislature nearly closed the door at the statehouse. The Supreme Court closed it at the courthouse. What remains — the Bates theories, the independent-duty claims — is the narrow space between a failed state bill and a successful federal preemption ruling.
Idaho law still matters for Idaho plaintiffs, even after Durnell. Idaho follows a modified comparative negligence rule under Idaho Code § 6-801, which provides that a plaintiff’s recovery is not barred if the plaintiff’s negligence was not as great as the defendant’s, though any damages are reduced in proportion to the plaintiff’s share of fault. For a Roundup plaintiff, this means the defense might argue that the plaintiff failed to wear protective equipment or used the product in a manner inconsistent with the label directions — and if the jury assigns the plaintiff a share of fault, the recovery is reduced by that percentage. If the plaintiff’s fault reaches 51% or more, recovery is barred entirely.
“if such negligence or comparative responsibility was not as great as the negligence, gross negligence or comparative responsibility of the person against whom recovery is sought”
Idaho Code § 6-801. This is the rule that governs fault allocation in any Idaho Roundup case that survives the Durnell preemption bar — and it is one more reason why the specifics of how a plaintiff used Roundup, what warnings were on the label at the time, and what protective measures were available matter to the case.
What Your Case Is Worth After Durnell: An Honest Assessment
We are going to give you the honest evaluation that most pages on this subject will not. The case-value picture after Durnell is not what it was before Durnell, and pretending otherwise would be a disservice to every person reading this page who is trying to make decisions about their future with a cancer diagnosis in their hands.
For new failure-to-warn claims — claims filed after the Durnell decision by plaintiffs who have not previously settled or obtained a verdict — the value is currently zero. The Durnell holding preempts those claims at the pleading stage. A court will likely dismiss a complaint that pleads only failure-to-warn before the plaintiff ever gets to discovery, before any evidence is exchanged, before any expert is deposed. This is not a matter of a weak case that might lose at trial. This is a matter of a case that cannot be brought because the legal theory it relies on has been federally preempted.
For pre-Durnell cases — cases that were filed, settled, or reduced to final judgment before the Supreme Court’s June 25, 2026 ruling — the value depends on procedural posture. Cases with final settlements that have been paid are unaffected; the money has been received and the release has been signed. Cases with final verdicts that were affirmed on appeal before Durnell may also be unaffected, depending on whether the appellate process was complete. Cases that were on appeal when Durnell was decided — including the Durnell case itself — have been reversed. Cases that were pending in trial courts when Durnell was decided face an immediate motion to dismiss that will likely succeed on the failure-to-warn theory.
For non-labeling theories — design defect, negligent testing, manufacturing defect — the value is uncertain but potentially significant. These theories, if they survive preemption challenges under Bates, present the same underlying injury profile that produced seven-figure verdicts under the failure-to-warn theory. Non-Hodgkin’s lymphoma is a severe, costly, life-altering cancer. The economic damages alone — past and future medical expenses, lost wages, diminished earning capacity — can reach well into seven figures for a working-age plaintiff with aggressive disease requiring multi-line therapy. The non-economic damages — pain and suffering, emotional distress, loss of quality of life — add substantially to that figure. If a non-preempted theory reaches a jury, and if the jury accepts the causal link between glyphosate and NHL, the case value could be comparable to pre-Durnell verdicts.
But that is two “ifs” — and neither is guaranteed. The first “if” is whether the court accepts that the non-labeling theory is genuinely independent of labeling requirements and not a failure-to-warn claim in disguise. The second “if” is whether the jury accepts the causation evidence without the failure-to-warn framework that made the causal narrative compelling to pre-Durnell juries. A design defect claim requires the plaintiff to prove that the product was unreasonably dangerous as designed — a different and in some ways harder burden than proving the manufacturer should have warned about a known risk.
Missouri, where the Durnell case originated, allows punitive damages in product liability cases. Under Missouri law, punitive damages require proof by clear and convincing evidence that the defendant intentionally harmed the plaintiff without just cause or acted with a deliberate and flagrant disregard for the safety of others. Mo. Rev. Stat. § 510.261. If a non-preempted claim — say, negligent testing — produces evidence that Monsanto knew glyphosate was associated with cancer risks and failed to conduct adequate testing or suppressed unfavorable research, the punitive damages standard may be met. Missouri’s punitive damages framework is part of what made it a plaintiff-favorable venue for product liability cases, and it is part of what is at stake when a case is dismissed on preemption grounds before that evidence can be presented.
For Idaho plaintiffs, the damages picture is different. Idaho’s wrongful death statute — Idaho Code § 5-311 — authorizes the decedent’s heirs or personal representatives to maintain an action for damages when death is caused by the wrongful act or neglect of another. Idaho’s survival statute — Idaho Code § 5-327(1) — provides that a cause of action for personal injury does not abate upon death, with the personal representative maintaining the survival action. These provisions matter for families who have lost a loved one to non-Hodgkin’s lymphoma after Roundup exposure, but they are only meaningful if a non-preempted theory survives to support the claim.
Past results depend on the facts of each case and do not guarantee future outcomes. The pre-Durnell Roundup settlements and verdicts that have been publicly reported — some reaching tens of millions of dollars — were built on the failure-to-warn theory that Durnell has now preempted. We cannot tell you that a post-Durnell case will produce a comparable result. We can tell you that the injury profile supports a case of that magnitude if the legal barrier can be overcome, and that the only way to know whether your specific facts support a non-preempted theory is a case-specific evaluation with a lawyer who understands the Bates-Durnell distinction.
Evidence Preservation: Why It Matters When the Law Seems Settled Against You
Here is something most people do not understand about toxic tort litigation: the law changes. Statutes get amended. Supreme Court decisions get narrowed by subsequent rulings. Preemption doctrines get modified by Congress. New scientific evidence emerges that shifts the regulatory landscape. What is a closed door today may be an open door in two years, or five, or ten — but only if the evidence that would support a claim still exists when the door opens.
If you used Roundup and developed non-Hodgkin’s lymphoma, the evidence of your exposure and your injury is perishable. It is dying on a clock that started the day you stopped spraying and that accelerates with every year that passes. Here is what exists, who holds it, how fast it disappears, and what to do about it right now.
Roundup purchase receipts, product containers, and usage logs. These establish the duration, frequency, and intensity of your glyphosate exposure — the foundation of specific causation. If you bought Roundup at a hardware store, a farm supply, or a big-box retailer, your purchase records may exist in loyalty-program databases, credit card statements, or farm-supply account records. The physical product containers — the bottles, the jugs, the drums — may still be in your garage, your barn, your shed, or your employer’s storage area. These containers have labels that show the formulation, the EPA registration number, and the warning language that was on the product at the time you used it. Product containers degrade. Plastic becomes brittle and cracks. Labels fade and peel. Receipts fade. Memories of how often you sprayed, how much you mixed, what concentration you used, and what protective equipment you wore — all of that fades faster than the plastic. If you still have containers, photograph them from every angle, preserve the labels, and store them in a dry, protected location. If you have receipts, scan them. If you have usage logs — spray records, work orders, maintenance schedules — copy them now.
Complete medical records including pathology reports, treatment history, and oncologist notes. These document the non-Hodgkin’s lymphoma diagnosis, the specific subtype, the treatment course, and the prognosis. The pathology report — the document in which the pathologist identified your lymphoma subtype through microscopic examination and immunohistochemistry — is the single most important medical record in your case. It establishes what you have, at the cellular level. Your treatment records — the chemotherapy orders, the infusion logs, the radiation plans, the surgical notes, the bone marrow biopsy results — establish what the disease has cost you in medical intervention. Your oncologist’s notes establish your prognosis and your surveillance schedule. These records are generally stable in medical-provider systems, but provider retention policies vary, and practices close, merge, or purge records on schedules that can be as short as seven to ten years. Request your complete medical records now — not a summary, not an abstract, the full chart — and keep copies in your own possession.
Employment and occupational records showing Roundup handling duties. If you used Roundup at work — as a groundskeeper, a landscaper, a farmer, a park maintenance worker, a nursery employee, or in any occupation that involved regular herbicide application — your employment records document the scope and duration of your occupational exposure. Work orders, spray schedules, pesticide application logs, job descriptions, safety training records, and personnel files all contribute to the exposure picture. Employment records may be destroyed per company retention policies. Some employers purge personnel files within a few years of separation. If you are still employed, request your personnel file and any occupational exposure records now. If you are no longer employed, request them immediately — before they are destroyed.
Monsanto/Bayer internal corporate documents regarding glyphosate carcinogenicity research. Much of the internal corporate discovery from the prior Roundup multidistrict litigation — communications regarding the IARC classification, alleged ghostwriting of scientific literature, interactions with EPA officials during registration reviews, and internal toxicological assessments — has been produced in prior MDL proceedings. These documents may be available through the MDL document depository or may require independent subpoenas in new litigation. For non-preempted claims — particularly negligent testing and design defect — these documents are central. They may reveal what Monsanto knew about glyphosate’s carcinogenic potential, what testing it conducted, what testing it should have conducted, and whether its public-facing safety statements were consistent with its internal scientific assessments. This evidence is the backbone of any surviving post-Durnell case, and it is the evidence most likely to support a punitive damages theory under standards like Missouri’s deliberate-and-flagrant-disregard rule.
EPA registration files and the IARC monograph on glyphosate. These are public records that establish the regulatory framework underlying the preemption defense and the scientific disagreement at the heart of the causation debate. The EPA’s registration files for glyphosate — including its carcinogenicity assessment, its review of the IARC classification, and its registration review schedule — are available through EPA databases. The IARC monograph classifying glyphosate as “probably carcinogenic to humans” is available through IARC’s publications. These records are stable, but regulatory assessments can be revised — the EPA’s position on glyphosate carcinogenicity could change in a future registration review, which would affect the preemption analysis. Archiving the current regulatory record ensures that the scientific and regulatory landscape as it exists today is preserved for any future litigation.
The reason all of this matters — even when the Durnell decision has closed the main door — is that the legal landscape is not permanent. Congress could amend FIFRA to clarify that state tort claims are not preempted. The EPA could revise its carcinogenicity assessment of glyphosate, which would undermine the preemption defense. A future Supreme Court case could narrow Durnell’s holding. State legislatures could enact statutes restoring tort remedies for pesticide injuries. Any of these changes could reopen doors that Durnell closed — but only for plaintiffs who can prove their cases, and only for plaintiffs whose evidence still exists.
The preservation letter — the formal demand that a defendant and third parties preserve specific records and physical evidence — goes out the day you call us, not after the law changes. Because the evidence that dies today cannot be resurrected by a legal victory tomorrow.
The Defense Playbook: How Monsanto Uses the Durnell Shield
When the Supreme Court gives a corporate defendant a preemption shield, the defendant does not use it sparingly. Monsanto and Bayer have already demonstrated, in the years of Roundup litigation that preceded Durnell, that they are sophisticated, well-funded litigators who deploy every available defense at every stage of a case. Durnell gives them a new weapon, and they will use it. Here are the plays you should expect — and the counter to each.
Play 1: The preemption sweep. Monsanto will file a motion to dismiss at the pleading stage arguing that every claim in the complaint — including design defect, negligent testing, and manufacturing defect — is preempted by FIFRA under Durnell. The argument will be that these claims are “failure-to-warn in disguise” — that any claim premised on the carcinogenic risks of glyphosate necessarily requires Monsanto to add a cancer warning to its label, and is therefore preempted. The counter is Bates v. Dow Agrosciences, 544 U.S. 431, 444 (2005), which held that design defect, negligent testing, and manufacturing defect claims are not preempted because they do not require labeling changes. The complaint must be drafted to plead these theories as independent-duty claims — claims that Monsanto owed a duty to design a safe product, to test adequately, and to manufacture without defects — not as claims that depend on the inadequacy of the label. The distinction is subtle, and a poorly drafted complaint will blur it. A well-drafted complaint will make the distinction unmistakable.
Play 2: The EPA deference argument. Monsanto will argue that the EPA’s assessment that glyphosate is “not likely to be carcinogenic to humans” is entitled to regulatory deference, and that a jury cannot second-guess the EPA’s scientific judgment. This argument is designed to undermine the causation element of any surviving claim — if the EPA says glyphosate is not carcinogenic, how can a jury find that it caused the plaintiff’s cancer? The counter is that regulatory deference does not equate to scientific certainty. The EPA’s assessment is one body of scientific opinion; IARC’s classification is another. A jury is entitled to hear both and to weigh the evidence. The EPA’s assessment was based on studies and data that the plaintiff’s experts can challenge — including the quality of the studies the EPA relied on, the studies it disregarded, and the influence of the manufacturer’s own submissions on the regulatory process. Expert witnesses in epidemiology, toxicology, and oncology can present the evidence supporting a causal association between glyphosate and non-Hodgkin’s lymphoma, and the jury can decide which scientific body’s assessment is more credible.
Play 3: The labeling-in-disguise characterization. For any claim that references the adequacy of Monsanto’s warnings or safety communications — even if the claim is labeled design defect or negligent testing — Monsanto will argue that the claim is实质 a failure-to-warn claim and is therefore preempted. This is the most dangerous play because it tests the line between Bates and Durnell. The counter is careful claim construction: a design defect claim argues that the product was unreasonably dangerous because a safer formulation was available, not that the label should have said more. A negligent testing claim argues that Monsanto failed to conduct adequate testing, not that it failed to report its testing results on the label. The claims must be built on what Monsanto did or failed to do in the laboratory and in the formulation — not on what it did or failed to do on the label.
Play 4: Settlement pressure with a ticking clock. Monsanto may offer nominal settlements to plaintiffs with pending claims — settlements that are significantly less than pre-Durnell values, framed as “take it now before we move to dismiss on preemption grounds.” The pressure is real: if the plaintiff declines and the court grants a preemption motion, the plaintiff gets nothing. The counter is a case-specific evaluation of whether the plaintiff’s claims include viable non-preempted theories. If they do, the settlement value should reflect the full case — not the preemption-discounted value. If they do not, the settlement may be the best available outcome. This is a decision that requires an honest lawyer, not a lawyer who tells every client that every case is worth millions.
Play 5: The regulatory safe harbor. Monsanto will argue that because it complied with all FIFRA requirements — because it registered its product, submitted its label, and obtained EPA approval — it is entitled to a regulatory safe harbor that insulates it from all tort liability, not just failure-to-warn claims. The counter is that FIFRA’s preemption clause is specific — it preempts state-law requirements for labeling or packaging, not all state-law requirements. Bates confirmed this: claims based on independent duties are not preempted. Compliance with FIFRA’s registration and labeling requirements does not immunize a manufacturer from claims that it designed a defective product, tested negligently, or manufactured a product with defects. The safe harbor is limited to the label, not to the entire product.
How a Surviving Case Is Built: The Proof Story
If you are reading this page and you have non-Hodgkin’s lymphoma and a history of Roundup exposure, and you want to know whether you have a case that can survive Durnell, here is how that case is actually built — not in the abstract, but step by step, from the first phone call through the evidence that would reach a jury.
Week one: the case evaluation. The first conversation is not a sales pitch. It is an honest assessment of your exposure history, your medical diagnosis, and the current legal landscape. We need to know: when did you use Roundup, how often, for how many years, in what concentration, and through what route of exposure (spraying, mixing, loading, cleaning equipment)? We need to know: when were you diagnosed with non-Hodgkin’s lymphoma, what subtype, what treatment have you received, what is your current status? And we need to know: do you still have product containers, receipts, employment records, or other evidence of your exposure? This conversation determines whether the facts support a non-preempted theory — not whether the failure-to-warn theory is available, because it is not.
Weeks two through four: the preservation effort. If the facts support a potential claim, the preservation letters go out immediately. These are formal demands directed to Monsanto/Bayer, to any employer whose records document your Roundup handling duties, and to any third party — a farm supply company, a hardware store, a commercial pesticide distributor — whose records might document your purchase history. The preservation letter puts the recipient on notice that specific records and physical evidence are relevant to potential litigation and must be preserved. If the recipient destroys those records after receiving the letter, the court may impose sanctions — including an adverse-inference instruction that allows the jury to assume the destroyed evidence was as damaging as the plaintiff claims. The preservation letter is the first shot in the evidence war, and it is fired before any complaint is filed.
Months one through three: the complaint and the preemption motion. The complaint is drafted to plead non-preempted theories — design defect, negligent testing, manufacturing defect — as independent-duty claims grounded in Bates. Each claim is built on what Monsanto did or failed to do apart from the label: the formulation it chose, the testing it conducted, the research it possessed, the alternative designs that were available. The complaint anticipates the preemption motion that Monsanto will file and is structured to survive it. When the motion to dismiss arrives — and it will — the response brief argues the Bates distinction: these claims do not require labeling changes; they require the manufacturer to have designed, tested, and manufactured a non-defective product. If the court agrees, the case proceeds to discovery. If the court disagrees, the case may be dismissed — and the dismissal may be appealed.
Months three through twelve: discovery. If the case survives the preemption motion, discovery is where the evidence is built. Written discovery — interrogatories, requests for production, requests for admission — targets Monsanto’s internal research records, its communications with EPA officials, its interactions with the scientific community, and its knowledge of glyphosate’s carcinogenic potential. Much of this evidence may already exist in the MDL document depository from prior Roundup litigation, but independent subpoenas may be needed to obtain documents specific to the plaintiff’s product, exposure period, and geographic region. Depositions of Monsanto’s corporate representatives — the scientists who conducted the toxicological research, the regulatory affairs personnel who interacted with the EPA, the executives who made formulation and marketing decisions — are where the company’s choices are examined under oath.
Months six through eighteen: expert discovery. Expert witnesses are the backbone of any toxic tort case. For general causation — whether glyphosate can cause non-Hodgkin’s lymphoma in humans — the plaintiff needs an epidemiologist who can present the studies supporting the association, a toxicologist who can explain the mechanism by which glyphosate or its formulations may induce lymphomagenesis, and an oncologist who can explain the biological plausibility of the association. For specific causation — whether this plaintiff’s non-Hodgkin’s lymphoma was caused by their Roundup exposure — the plaintiff needs an expert who can perform a differential diagnosis, ruling out other known risk factors for NHL (age, immunosuppression, certain viral infections, family history) and identifying the temporal relationship between exposure and diagnosis, the dose-response relationship, and the consistency of the exposure history with the known epidemiological data. Monsanto’s experts will argue that the epidemiological evidence is insufficient, that the IARC classification is an outlier, and that the EPA’s non-carcinogenicity finding should control. The battle of experts is where the case is won or lost — and it is a battle that requires resources, preparation, and lawyers who understand the science.
Months twelve through twenty-four: trial. If the case survives summary judgment — and Monsanto will file a summary judgment motion arguing that the expert testimony on causation is inadmissible — the case proceeds to trial. The trial is where the jury hears the science, sees the internal corporate documents, listens to the experts, and decides whether Roundup caused the plaintiff’s cancer and whether Monsanto is responsible. The jury that decides this case will be drawn from the community where the case is filed — in Missouri, that means Missouri jurors; in Idaho, that means Idaho jurors. The jury’s attitude toward corporate accountability, toward regulatory deference, and toward the scientific evidence will determine the outcome.
This is the proof story. It is not fast. It is not easy. And it is not guaranteed. But it is the path that Bates left open, and it is the path that a lawyer who understands the Durnell-Bates distinction can walk.
The First 72 Hours: What to Do Right Now
If you used Roundup and have been diagnosed with non-Hodgkin’s lymphoma — or if someone you love used Roundup and has died from non-Hodgkin’s lymphoma — here is what to do in the next 72 hours. Not next month. Not after you talk to the insurance company. Not after you sign anything. Now.
Document your exposure history in writing. Sit down with a pen and paper or a keyboard and write out everything you can remember about your Roundup use. When did you first use it? How often did you use it — daily, weekly, seasonally? How many years did you use it? What concentration did you mix? Did you spray it, mix it, load it, or clean equipment that had been used with it? Did you wear gloves, a mask, protective clothing? Did you get it on your skin? Did you inhale the spray? Where did you use it — at home, at work, on a farm, at a park, at a school, at a commercial property? Write this down now, while the memories are as fresh as they will ever be. Every year that passes, the details blur. The document you create today is evidence.
Photograph and preserve every product container you can find. If you still have Roundup containers — in your garage, your barn, your shed, your employer’s storage area — photograph them from every angle. Photograph the label, the EPA registration number, the formulation, the warning language, the lot number if visible. Then store the containers in a dry, protected place. Do not throw them away. Do not return them to the store. Do not let an employer dispose of them. Those containers are physical evidence — they prove what formulation you used, what warnings were on the product at the time, and what EPA registration number the product carried. Every container that gets discarded is a piece of evidence that can never be replaced.
Request your complete medical records. Contact every physician, every hospital, every clinic, and every laboratory that has been involved in your non-Hodgkin’s lymphoma diagnosis and treatment. Request the complete chart — not a summary, not an abstract, the full record. This includes the pathology report that identified your lymphoma subtype, the imaging reports (CT, PET, MRI), the treatment orders and infusion logs, the bone marrow biopsy results if applicable, the oncologist’s progress notes, and the discharge summaries from any hospitalizations. You are entitled to your own medical records. Request them in writing, and keep copies of the request and the records.
Request your employment records. If you used Roundup at work, contact your employer’s human resources department and request your complete personnel file, including job descriptions, safety training records, any occupational exposure monitoring records, and any pesticide application logs or spray schedules. If you are no longer employed there, request the records immediately — employer retention policies vary, and some employers purge personnel files within a few years of separation. If your employer is no longer in business, contact the state labor department or any successor entity that may have inherited the records.
Do not sign anything. Do not sign a release, a settlement agreement, a waiver, or any document that anyone — an insurance company, a former employer, a chemical distributor, or a lawyer who is not yours — puts in front of you. Do not give a recorded statement to anyone. Do not agree to anything over the phone. If someone contacts you and asks you to sign something or to talk about your Roundup use on a recording, say nothing and call us. The documents you sign today may waive rights you do not know you have — including rights that may become valuable if the law changes.
Do not post about your case on social media. Do not write about your Roundup use, your cancer diagnosis, or your legal intentions on Facebook, Twitter, Instagram, TikTok, or any other platform. Social media posts are discoverable in litigation, and defense lawyers mine them for contradictions — a post that says “feeling great today” can be used to argue that your pain-and-suffering damages are exaggerated, even if the post was from a good day in the middle of a terrible treatment cycle. Assume that everything you post will be read by Monsanto’s lawyers and used against you.
Call for an honest case evaluation. This is the step that most people delay — and it is the step that matters most, because the evidence clock is running. The preservation letter goes out the day you call us. The case evaluation is free. The conversation is confidential. And the answer you get will be the truth — including, if necessary, the truth that the failure-to-warn theory is preempted and your case depends on non-labeling theories that are uncertain but potentially viable. We would rather tell you the hard truth and earn your trust than tell you what you want to hear and fail you later. If your toxic tort claim has a path, we will find it. If it does not, we will tell you — and we will tell you what to preserve in case the path opens later.
Idaho Law: Your Rights and Deadlines
For Idaho residents affected by Roundup exposure, the state legal framework adds another layer to the post-Durnell analysis. Idaho imposes a two-year statute of limitations on personal injury claims. This means you have two years from the date your cause of action accrues to file a lawsuit, or your claim is forever barred. In a toxic tort case, the accrual date is a critical question — it may be the date of diagnosis, the date you discovered or should have discovered the connection between your exposure and your injury, or another date depending on the specific facts and the applicable legal doctrine. Because this timing question is case-specific and because the Durnell decision may affect when the clock starts on claims that were previously viable but are now preempted, you should not assume you have plenty of time. You should assume the clock is running and call us for a case-specific evaluation.
Idaho’s modified comparative negligence rule — Idaho Code § 6-801 — means that if you are partly at fault for your own injury, your recovery is reduced by your percentage of fault, and if your fault reaches 51% or more, you are barred from recovery entirely. In a Roundup case, the defense may argue that you failed to follow label directions, failed to wear protective equipment, or used the product in a manner inconsistent with its registered use. Every percentage point of fault assigned to you is money subtracted from your recovery — which is exactly why the defense works so hard to pin fault on the plaintiff.
For families who have lost a loved one to non-Hodgkin’s lymphoma after Roundup exposure, Idaho’s wrongful death statute — Idaho Code § 5-311 — authorizes the decedent’s heirs or personal representatives to maintain an action for damages against the person causing the death. Idaho’s survival statute — Idaho Code § 5-327(1) — provides that the cause of action for personal injury does not abate upon death, with the personal representative of the decedent’s estate maintaining the survival action. These provisions mean that even if the person who was exposed has died, the family’s claim may survive — but only if a non-preempted legal theory supports it, and only if the statute of limitations has not expired.
Idaho also considered — and defeated — a herbicide liability-immunity bill that would have shielded manufacturers from state-law tort claims. The fact that this bill was blocked at the state level means that Idaho’s tort system remains available as a forum for non-preempted claims. But the federal preemption established by Durnell applies in Idaho just as it does in every other state. The Idaho legislature’s rejection of statutory immunity does not undo the Supreme Court’s federal preemption ruling. What it means is that Idaho’s courts remain open to claims that are not preempted — the Bates claims, the independent-duty claims — even as they are closed to claims that are.
Frequently Asked Questions
Can I still file a Roundup lawsuit after the Supreme Court’s Monsanto v. Durnell decision?
It depends on what legal theory your case relies on. If your case is built on a failure-to-warn theory — the argument that Monsanto should have put a cancer warning on the Roundup label — the Durnell decision likely bars that claim under FIFRA preemption. A court will probably dismiss it. If your case can be built on non-labeling theories — design defect, negligent testing, manufacturing defect — those claims may survive under Bates v. Dow Agrosciences, 544 U.S. 431 (2005), which held that such claims are not preempted because they do not require labeling changes. The only way to know whether your specific facts support a surviving theory is a case-specific evaluation with a lawyer who understands the Durnell-Bates distinction.
What did the Supreme Court actually decide in Monsanto v. Durnell?
The Supreme Court held, 7-2, that FIFRA expressly preempts state-law label-based failure-to-warn claims against Monsanto for Roundup exposure where the claim would require Monsanto to add a cancer warning to its label. Monsanto Co. v. Durnell, No. 24-1068 (U.S. June 25, 2026). Justice Kavanaugh wrote the majority opinion, joined by Chief Justice Roberts and Justices Thomas, Alito, Sotomayor, Kagan, and Barrett. Justice Jackson dissented, joined by Justice Gorsuch. The Court reversed the Missouri Court of Appeals. The certiorari was granted on a limited question — whether FIFRA preempts a label-based failure-to-warn claim where EPA has not required the warning — and the Court answered that question. It did not address whether FIFRA preempts other tort theories.
I was already diagnosed with non-Hodgkin’s lymphoma before the Durnell decision. Does the ruling affect my existing case?
If your case was already settled and the settlement has been paid, Durnell does not affect you — the release has been signed and the money has been received. If your case was pending in trial court or on appeal when Durnell was decided, Monsanto will likely file a motion to dismiss or a motion based on the Durnell ruling, arguing that your failure-to-warn claims are preempted. If your case includes non-labeling theories — design defect, negligent testing — those claims may survive. If your case relied solely on failure-to-warn, it faces dismissal. You need a lawyer to evaluate your case’s specific procedural posture and claim structure immediately.
Is glyphosate actually linked to non-Hodgkin’s lymphoma?
The scientific community is divided. The International Agency for Research on Cancer (IARC), the cancer research arm of the World Health Organization, classified glyphosate as “probably carcinogenic to humans” (Group 2A) in 2015, based on epidemiological studies showing an association between glyphosate exposure and non-Hodgkin’s lymphoma, along with mechanistic and animal-study evidence. The EPA has consistently maintained that glyphosate is “not likely to be carcinogenic to humans.” This divergence is the scientific conflict at the heart of the Roundup litigation — and it is the conflict that the Durnell preemption ruling effectively removes from the jury’s consideration in failure-to-warn cases. In non-preempted cases, a jury may still hear both scientific assessments and weigh the evidence.
What is the difference between a failure-to-warn claim and a design defect claim?
A failure-to-warn claim argues that the manufacturer should have put an adequate warning on the product’s label — in the Roundup context, that Monsanto should have added a cancer warning. This claim, if successful, requires a labeling change, and the Supreme Court held in Durnell that FIFRA preempts it. A design defect claim argues that the product was unreasonably dangerous as designed — that its risks could have been reduced or eliminated through an alternative formulation. This claim, if successful, does not require a labeling change; it requires the manufacturer to have designed a different product. The Supreme Court held in Bates that design defect claims are not preempted by FIFRA because they do not impose labeling requirements. The difference is whether the claim requires the manufacturer to change its label (preempted) or to change its product (potentially not preempted).
I used Roundup at work for years. Does that change my case?
Occupational exposure — regular, sustained, high-level exposure over years or decades — is typically stronger evidence of specific causation than occasional residential use. If you used Roundup as a groundskeeper, landscaper, farmer, agricultural worker, park maintenance worker, or in any occupation involving routine herbicide application, your exposure history may support a stronger causal inference than a homeowner who sprayed Roundup on weeds a few times a year. Your employment records — job descriptions, spray schedules, work orders, safety training records — are critical evidence of the scope and duration of your exposure. Request those records immediately, because employer retention policies may result in their destruction.
My family member died from non-Hodgkin’s lymphoma after using Roundup. Can we still bring a claim?
Possibly, if a non-preempted theory supports the claim and the statute of limitations has not expired. Idaho’s wrongful death statute — Idaho Code § 5-311 — authorizes the decedent’s heirs or personal representatives to maintain an action for damages. Idaho’s survival statute — Idaho Code § 5-327(1) — provides that the cause of action does not abate upon death. Missouri has its own wrongful death framework. The Durnell preemption ruling applies to these claims just as it applies to living plaintiffs’ claims — failure-to-warn theories are preempted, but non-labeling theories may survive. If your loved one’s case was already filed and pending when Durnell was decided, the case needs immediate evaluation. If no case has been filed, the wrongful death clock is running, and evidence of your loved one’s Roundup exposure must be preserved before it disappears.
How long do I have to file a Roundup cancer lawsuit?
Idaho imposes a two-year statute of limitations on personal injury claims. The specific date from which the clock starts — the date of diagnosis, the date of discovery, or another trigger — depends on the facts of your case and the applicable legal doctrine. Missouri has its own limitations period. Because the Durnell decision may affect the accrual analysis for claims that were previously viable under the failure-to-warn theory, and because the statute of limitations is a hard deadline that cannot be extended, you should not wait. The day you call is the day the preservation letter goes out and the day the clock starts working for you instead of against you.
Will Congress or the EPA change the rules that Durnell established?
Possibly. Congress could amend FIFRA to clarify that state tort claims are not preempted by the statute’s labeling provisions. The EPA could revise its carcinogenicity assessment of glyphosate in a future registration review, which could undermine the preemption defense by changing the federal regulatory judgment that the Durnell majority relied on. State legislatures could enact statutes restoring tort remedies for pesticide injuries. Any of these changes could reopen doors that Durnell closed — but legislative and regulatory changes are unpredictable, and they may take years. What you can control is whether your evidence still exists when the law changes. That is why evidence preservation matters now, regardless of the current legal landscape.
What if a lawyer told me I have a strong Roundup case?
Ask that lawyer whether they have read the Monsanto v. Durnell decision and whether they understand the distinction between failure-to-warn claims (preempted) and non-labeling tort theories (potentially not preempted under Bates). If the lawyer’s analysis does not address Durnell and Bates, the analysis is outdated. Many lawyers who handled Roundup cases before Durnell have not yet updated their practice to reflect the post-Durnell landscape. Some are still signing up failure-to-warn cases that will be dismissed at the pleading stage. A lawyer who tells you the Durnell ruling does not affect your case without explaining why — and without identifying the specific non-preempted theory your case relies on — is not giving you an honest evaluation.
How much does it cost to hire Attorney911 for a Roundup case?
Nothing upfront. We work on contingency — 33.33% before trial, 40% if the case goes to trial. We do not get paid unless we win your case. The consultation is free. The case evaluation is free. The conversation is confidential. And the answer you get will be the truth — including, if necessary, the truth that your case faces serious legal barriers and may not be viable under current law. We would rather tell you that now and preserve your evidence for the future than sign you up for a case that will be dismissed.
What should I do with my Roundup containers and receipts?
Keep them. Photograph them. Store them in a dry, protected location. Do not throw them away, return them to the store, or let an employer dispose of them. Those containers and receipts are physical evidence of what product you used, what formulation it was, what warnings were on the label at the time of your use, and when and where you purchased it. Every container that gets discarded is a piece of evidence that can never be replaced — and if the law changes to reopen the courthouse door, the evidence you preserved may be the difference between a case and no case.
Why Attorney911: Real Lawyers, Honest Answers
We are not the firm that tells every caller their case is worth millions. We are the firm that tells you the truth — and then fights from wherever that truth leaves you.
Ralph Manginello has spent 27+ years in courtrooms, including federal court. He was a journalist before he was a lawyer — a reporter who learned to dig for the facts that institutions prefer to keep buried — and he brought that instinct into the courtroom. He is the managing partner of The Manginello Law Firm, PLLC, licensed in Texas since November 6, 1998 (Texas Bar #24007597), admitted to the U.S. District Court for the Southern District of Texas. He handles toxic tort cases, product liability cases, catastrophic injury cases, and wrongful death cases — the cases where a corporation’s product or a company’s choices destroyed a life and the family needs someone who knows how to make the company answer for it. Ralph’s background is on our site, and every word of it is true.
Lupe Peña spent years inside a national insurance-defense firm — the rooms where claims are priced, reserves are set, and denial strategies are developed. He sat across the table from the people who were deciding how to minimize, delay, and devalue claims exactly like yours. Now he sits on your side of the table. He is fluent in Spanish and conducts full client consultations in Spanish without an interpreter — because a family in crisis should not have to work through a translator to understand their own rights. Lupe’s background is on our site too.
What Ralph and Lupe bring to a post-Durnell Roundup case is the thing most firms cannot: the willingness to read a Supreme Court decision carefully, identify the distinction between what the Court decided and what it left open, and build a case on the open ground. The failure-to-warn theory is dead. The toxic tort landscape has changed. But Bates v. Dow Agrosciences is still good law, and the independent-duty theories it preserved are still available — for the lawyer who knows they exist and knows how to plead them.
We serve your family fully in Spanish. Hablamos Español. The consultation is free. The case evaluation is free. The preservation letter goes out the day you call. And we do not get paid unless we win your case.
Past results depend on the facts of each case and do not guarantee future outcomes.
This page is legal information, not legal advice. Every case is different. The Durnell decision has fundamentally changed the legal landscape for Roundup cancer claims, and the information on this page reflects our understanding of that decision and its implications as of the date of publication. The law may continue to evolve through legislative action, regulatory revision, or further appellate litigation. For an evaluation of your specific circumstances, call us.
If you used Roundup and developed non-Hodgkin’s lymphoma — or if someone you love did — call 1-888-ATTY-911. Free consultation. No fee unless we win. Twenty-four hours a day, seven days a week, a real person answers — not an answering service, not a robot, a person who works for this firm and knows why you are calling. The evidence clock is running. The law may change. But the evidence you preserve today is the evidence that makes a case possible tomorrow.
Call 1-888-ATTY-911. Or contact us through our site. The conversation is free. The truth is free. And the fight — if your case has one — starts the day you call.